Hyoscine butylbromide
- Generic Name
- Hyoscine butylbromide
- Brand Names
- Buscopan
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30NO4
- CAS Number
- 7182-53-8
- Unique Ingredient Identifier
- 2Z3E1OF81V
- Background
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, ...
- Indication
Used to treat abdmoninal cramping and pain .
- Associated Conditions
- Gastrointestinal spastic and hypermotility disorders, Infantile Hypertrophic Pyloric Stenosis, Menstrual Distress (Dysmenorrhea), Muscle Spasms, Pain, Primary Dysmenorrhoea, Stiffness of the Urinary Tract, Acute biliary spasm, Acute gastrointestinal spasms, Acute genitourinary spasms, Genitourinary smooth muscle spasm
- Associated Therapies
- Analgesia, Smooth muscle relaxation prior to radiological procedures therapy
Effect of Hyoscine- Bromide on Duration of the First Stage of Labor
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT06056869
- Locations
- 🇪🇬
Ain Shams University maternity hospital, Cairo, Cairo/القاهرة, Egypt
The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- National University of Malaysia
- Target Recruit Count
- 110
- Registration Number
- NCT04349722
- Locations
- 🇲🇾
National University Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia
Reclassifying Constipation Using Imaging and Manometry
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 120
- Registration Number
- NCT03226145
- Locations
- 🇬🇧
Queen Mary University of London, London, United Kingdom
🇬🇧University College London, London, United Kingdom
🇬🇧University of Nottingham, Nottingham, Notts, United Kingdom
Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 300
- Registration Number
- NCT03055390
- Locations
- 🇪🇬
Kasr Alainy medical school, Cairo, Egypt
Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Ahmed M Maged, MD
- Target Recruit Count
- 200
- Registration Number
- NCT02824679
Effect of Buscopan on Gastrointestinal Imaging Quality With Probe-based Confocal Laser Endomicroscopy
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 150
- Registration Number
- NCT02725398
- Locations
- 🇨🇳
Xijing Hospital of Digestive Diseases, Xi'an, Shaanxi, China
Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02516098
- Locations
- 🇨🇦
Boehringer Ingelheim Investigational Site, Bloemfontein, Canada
Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02261077
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 527
- Registration Number
- NCT02242292
Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT01734902
- Locations
- 🇩🇪
202.846.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.